source
- Swiss startup Vaderis raises $152 million to fund Phase 3 trial of rare bleeding disorder therapyVaderis Therapeutics, a 13‑person Swiss biotech, announced a $152 million Series B financing round aimed at advancing its experimental therapy into a Phase 3 study. The company is testing a treatm…
- Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series AYing Huang has spent the past seven years building up one of the leading cancer cell therapy players. Now, just weeks after announcing his departure as Legend Biotech's CEO, Huang is stepping ...Endpoints · 37m ago↗ source